PE20030474A1 - Compuesto que inhibe la liberacion de citoquinas inflamatorias - Google Patents

Compuesto que inhibe la liberacion de citoquinas inflamatorias

Info

Publication number
PE20030474A1
PE20030474A1 PE2002000925A PE2002000925A PE20030474A1 PE 20030474 A1 PE20030474 A1 PE 20030474A1 PE 2002000925 A PE2002000925 A PE 2002000925A PE 2002000925 A PE2002000925 A PE 2002000925A PE 20030474 A1 PE20030474 A1 PE 20030474A1
Authority
PE
Peru
Prior art keywords
aryl
alkyl
pyrimidin
fluorophenyl
heteroaryl
Prior art date
Application number
PE2002000925A
Other languages
English (en)
Inventor
Matthew John Laufersweiler
Michael Philip Clark
Jane Far-Jine Djung
Biswanath De
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of PE20030474A1 publication Critical patent/PE20030474A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20Spiro-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

SE REFIERE A PIRIMIDIN-PIRAZOLONAS CONDENSADAS DE FORMULA I DONDE R ES H, O[CH2]kR3, NR4aR4b; R3 ES ALQUILO, HIDROCARBILO CICLICO, HETEROCICLILO, ARILO, HETEROARILO; k ES 0-5; R4a Y R4b SON H, -[C(R5aR5b)]xR6, R5a Y R5b SON H, OR7, N(R7)2, CO2R7, CON(R7)2, ALQUILO; R6 ES OR7, N(R7)2, CO2R7, CON(R7)2, ARILO, HETEROARILO; R7 ES H, ALQUILO, ARILO; x ES 0-5; R1 ES ARILO, HETEROARILO; R2a, R2b SON H, O(CH2)jR8, (CH2)jNR9aNR9b, (CH2)jCO2R10, (CH2)jOCO2R10, ENTRE OTROS, R8, R9a, R9b, R10 SON H, ALQUILO; R9a, R9b JUNTOS FORMAN UN ANILLO CARBOCICLICO, HETEROCICLICO DE 3 A 7 ATOMOS, O DOS R10 FORMAN JUNTOS UN ANILLO CARBOCICLICO, HETEROCICLICO; j ES 0-5; m Y n SON 1-5, m+n ES 0-6. SON COMPUESTOS PREFERIDOS ESTER METILICO DEL ACIDO 2-(4-FLUOROFENIL)-3-(2-METILSULFANIL-PIRIMIDIN-4-IL)-3-OXO-PROPIONICO; 2-(4-FLUOROFENIL)-3-[2(S)-(1-FENILETILAMINO)-PIRIMIDIN-4-IL]-5,10-DIHIDROPIRAZOLO[1,2-b]FTALAZIN-1-ONA; 2-(4-FLUOROFENIL)-3-[2-(1-FENILETILAMINO)-PIRIMIDIN-4-IL]-5,8-DIHIDROPIRAZOLO[1,2-a]PIRIDAZIN-1-ONA. LOS COMPUESTOS INIHIBEN LA LIBERACION EXTRACELULAR DE CITOQUINAS INFLAMATORIAS
PE2002000925A 2001-09-20 2002-09-20 Compuesto que inhibe la liberacion de citoquinas inflamatorias PE20030474A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32362501P 2001-09-20 2001-09-20

Publications (1)

Publication Number Publication Date
PE20030474A1 true PE20030474A1 (es) 2003-07-22

Family

ID=23259997

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2002000925A PE20030474A1 (es) 2001-09-20 2002-09-20 Compuesto que inhibe la liberacion de citoquinas inflamatorias
PE2002000924A PE20030446A1 (es) 2001-09-20 2002-09-20 6-7-DIHIDRO-5H-PIRAZOLO[1,2-a]PIRAZOL-1-ONAS ESPIROCICLICAS QUE CONTROLAN CITOQUINAS INFLAMATORIAS
PE2002000923A PE20030430A1 (es) 2001-09-20 2002-09-20 6,7-DIHIDRO-5H-PIRAZOLO[1,2-a]PIRAZOL-1-ONAS QUE CONTROLAN CITOQUINAS INFLAMATORIAS

Family Applications After (2)

Application Number Title Priority Date Filing Date
PE2002000924A PE20030446A1 (es) 2001-09-20 2002-09-20 6-7-DIHIDRO-5H-PIRAZOLO[1,2-a]PIRAZOL-1-ONAS ESPIROCICLICAS QUE CONTROLAN CITOQUINAS INFLAMATORIAS
PE2002000923A PE20030430A1 (es) 2001-09-20 2002-09-20 6,7-DIHIDRO-5H-PIRAZOLO[1,2-a]PIRAZOL-1-ONAS QUE CONTROLAN CITOQUINAS INFLAMATORIAS

Country Status (33)

Country Link
US (2) US6566357B1 (es)
EP (3) EP1427728B1 (es)
JP (3) JP2005504082A (es)
KR (4) KR100623879B1 (es)
CN (3) CN1250551C (es)
AR (3) AR037237A1 (es)
AT (3) ATE356126T1 (es)
AU (2) AU2002334641B2 (es)
BR (3) BR0212905A (es)
CA (3) CA2461073A1 (es)
CO (3) CO5560590A2 (es)
CY (1) CY1106398T1 (es)
CZ (3) CZ2004361A3 (es)
DE (3) DE60202782T2 (es)
DK (2) DK1427732T3 (es)
EG (2) EG24413A (es)
ES (3) ES2282459T3 (es)
HK (2) HK1071366A1 (es)
HU (3) HUP0402378A3 (es)
IL (3) IL160741A0 (es)
MA (3) MA27066A1 (es)
MX (3) MXPA04002569A (es)
MY (2) MY129329A (es)
NO (2) NO20041594L (es)
NZ (3) NZ531123A (es)
PE (3) PE20030474A1 (es)
PL (3) PL370362A1 (es)
PT (3) PT1427727E (es)
RU (3) RU2272040C2 (es)
SA (1) SA03230529B1 (es)
SK (3) SK1502004A3 (es)
WO (3) WO2003024973A1 (es)
ZA (3) ZA200401260B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849627B2 (en) 2001-09-20 2005-02-01 The Procter & Gamble Company 6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines
US6730668B2 (en) * 2001-09-20 2004-05-04 The Procter & Gamble Company 6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines
US7087615B2 (en) 2001-09-20 2006-08-08 The Procter & Gamble Company 6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which provide analgesia
US7473695B2 (en) * 2001-10-22 2009-01-06 Mitsubishi Tanabe Pharma Corporation 4-imidazolin-2-one compounds
US6677337B2 (en) * 2002-03-19 2004-01-13 The Procter & Gamble Company 1,2-dihydropyrazol-3-ones which controls inflammatory cytokines
CA2497007A1 (en) * 2002-09-09 2004-03-18 Amgen Inc. 1, 4, 5-substituted 1, 2-dihydro-pyrazol-3-one and 3-alkoxy-1h-pyrazole derivatives s tnf-alpha and interleukin lowering agents for the treatment of inflammations
ATE361296T1 (de) * 2003-04-03 2007-05-15 Merck Patent Gmbh Pyrazolidin-1,2-dicarbonsäure-1-((phenyl)-amid) 2-((phenyl)-amid) derivate als koagulationsfaktor xa inhibitoren zur behandlung von thrombosen
GB0308466D0 (en) 2003-04-11 2003-05-21 Novartis Ag Organic compounds
US7482356B2 (en) * 2003-11-10 2009-01-27 The Procter & Gamble Company Bicyclic pyrazolone cytokine inhibitors
AU2007238071B2 (en) * 2006-04-18 2012-06-07 Abbvie Inc. Antagonists of the vanilloid receptor subtype 1 (VR1) and uses thereof
DE102008060549A1 (de) 2008-12-04 2010-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung
DK2432767T3 (da) * 2009-05-19 2013-09-30 Dow Agrosciences Llc Forbindelser og fremgangsmåder til at kontrollere svampe
EP3308059B1 (en) 2015-06-15 2021-05-26 Cummins, Inc. Combustion chamber elasticity device
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
CN107033090B (zh) * 2017-05-16 2019-05-07 无锡捷化医药科技有限公司 一种1,2,3,4-四氢噌啉的制备方法
RU2721684C1 (ru) * 2019-09-06 2020-05-21 Федеральное государственное бюджетное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" Метил 2,3,8-триоксо-4-фенилтетрагидро-6Н-пиразоло[1,2-а]пирроло[2,3-c]пиразол-9а(1Н)-карбоксилаты
EP4422621A1 (en) * 2021-10-27 2024-09-04 Merck Sharp & Dohme LLC Spirotricycle ripk1 inhibitors and methods of uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1054291A (es) * 1963-02-26
GB1124982A (en) * 1965-02-09 1968-08-21 Lepetit Spa Diazabicyclo octanes and derivatives thereof
CH529154A (fr) 1969-10-27 1972-10-15 Lepetit Spa Procédé de préparation de pyrazolo (1,2-b) phtalazine-1,5 (10H)-diones
US5358924A (en) * 1991-03-21 1994-10-25 Bayer Aktiengesellschaft 3-hydroxy-4-aryl-5-oxo-pyrozoline derivatives, compositions and use
PT1481970E (pt) * 1999-09-07 2006-07-31 Syngenta Participations Ag Novos herbicidas
US6730668B2 (en) * 2001-09-20 2004-05-04 The Procter & Gamble Company 6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines

Also Published As

Publication number Publication date
EG24363A (en) 2009-03-04
EG24413A (en) 2009-05-25
MY129329A (en) 2007-03-30
CY1106398T1 (el) 2011-10-12
CZ2004345A3 (cs) 2004-06-16
ZA200401403B (en) 2004-08-30
RU2004111803A (ru) 2005-10-10
EP1427727A1 (en) 2004-06-16
DE60202782D1 (de) 2005-03-03
AR037145A1 (es) 2004-10-27
EP1427732A1 (en) 2004-06-16
HK1071366A1 (en) 2005-07-15
BR0212716A (pt) 2004-08-03
CO5560589A2 (es) 2005-09-30
US20030105084A1 (en) 2003-06-05
RU2299885C2 (ru) 2007-05-27
DE60218704T2 (de) 2007-11-08
MA27066A1 (fr) 2004-12-20
KR20040035837A (ko) 2004-04-29
RU2272040C2 (ru) 2006-03-20
SA03230529B1 (ar) 2008-06-21
CA2461072A1 (en) 2003-03-27
MXPA04002570A (es) 2004-05-31
BR0212905A (pt) 2004-10-13
US6821971B2 (en) 2004-11-23
PT1427727E (pt) 2005-06-30
AU2002327690B2 (en) 2006-07-20
KR100623879B1 (ko) 2006-09-19
SK1502004A3 (en) 2004-09-08
NZ531122A (en) 2005-09-30
AU2002334641B2 (en) 2007-03-29
CZ2004361A3 (cs) 2004-07-14
AR037237A1 (es) 2004-11-03
ES2268154T3 (es) 2007-03-16
RU2004111806A (ru) 2005-03-27
ZA200401260B (en) 2004-08-30
MA27064A1 (fr) 2004-12-20
SK1492004A3 (en) 2004-11-03
DK1427728T3 (da) 2007-07-09
KR20040035835A (ko) 2004-04-29
NZ531123A (en) 2006-08-31
KR20060036125A (ko) 2006-04-27
PE20030446A1 (es) 2003-07-21
HUP0500752A2 (en) 2006-01-30
DE60202782T2 (de) 2006-01-19
PL370415A1 (en) 2005-05-30
ZA200401402B (en) 2004-08-27
KR100656126B1 (ko) 2006-12-12
JP2005504083A (ja) 2005-02-10
CN1249066C (zh) 2006-04-05
ATE356126T1 (de) 2007-03-15
EP1427732B1 (en) 2006-07-12
KR20040035836A (ko) 2004-04-29
ES2237691T3 (es) 2005-08-01
AR037502A1 (es) 2004-11-17
CO5560590A2 (es) 2005-09-30
IL160742A0 (en) 2004-08-31
HUP0402378A2 (hu) 2005-02-28
EP1427727B1 (en) 2005-01-26
HK1071565A1 (en) 2005-07-22
BR0212673A (pt) 2004-08-24
WO2003024970A1 (en) 2003-03-27
CA2461071A1 (en) 2003-03-27
JP2005504081A (ja) 2005-02-10
US6566357B1 (en) 2003-05-20
CN1257905C (zh) 2006-05-31
DE60218704D1 (de) 2007-04-19
ES2282459T3 (es) 2007-10-16
CN1250551C (zh) 2006-04-12
SK1482004A3 (en) 2004-08-03
CA2461073A1 (en) 2003-03-27
RU2278864C2 (ru) 2006-06-27
WO2003024971A1 (en) 2003-03-27
PT1427732E (pt) 2006-12-29
IL160741A0 (en) 2004-08-31
NO20041605L (no) 2004-06-21
PT1427728E (pt) 2007-05-31
JP2005504082A (ja) 2005-02-10
MY129069A (en) 2007-03-30
WO2003024973A1 (en) 2003-03-27
HUP0402500A2 (hu) 2005-03-29
RU2004111805A (ru) 2005-04-10
CN1555375A (zh) 2004-12-15
IL160682A0 (en) 2004-08-31
MA27065A1 (fr) 2004-12-20
DE60213108T2 (de) 2007-02-08
HUP0402378A3 (en) 2008-10-28
CN1556811A (zh) 2004-12-22
HUP0402500A3 (en) 2008-10-28
MXPA04002569A (es) 2004-05-31
DK1427732T3 (da) 2006-10-30
CO5560579A2 (es) 2005-09-30
PL370351A1 (en) 2005-05-16
PL370362A1 (en) 2005-05-16
CN1555379A (zh) 2004-12-15
ATE332901T1 (de) 2006-08-15
MXPA04002574A (es) 2004-06-18
ATE287887T1 (de) 2005-02-15
PE20030430A1 (es) 2003-06-24
EP1427728A1 (en) 2004-06-16
NO20041594L (no) 2004-06-21
EP1427728B1 (en) 2007-03-07
CZ2004358A3 (cs) 2004-07-14
DE60213108D1 (de) 2006-08-24
NZ531063A (en) 2007-08-31

Similar Documents

Publication Publication Date Title
PE20030474A1 (es) Compuesto que inhibe la liberacion de citoquinas inflamatorias
AR011502A1 (es) Un compuesto substituido de acido 4-hidroxi-fenilalcanoico con actividad agonista a ppar-gamma, un metodo para prepararlo una composicion farmaceutica que lo contiene y uso del compuesto para la fabricacion de un medicamento
AR066528A1 (es) Peptidos inhibidores de la replicacion del virus de la hepatitis c
MEP61208A (en) Novel compounds having inhibitory activity against sodium-dependant transporter
BR9206861A (pt) Derivados de piperazina como antagonistas de 5-HT1A
PE20020524A1 (es) 7-oxo-piridopirimidinas como inhibidores de quinasas
IS1726B (is) Hliðstæðar aðferðir til framleiðslu á andróstenónafleiðu og milliefni notuð í aðferðunum
MX9102808A (es) Procedimiento para la preparacion de derivados de benzofurano substituidos.
DK0458387T3 (da) Isochromanderivater
KR860001791A (ko) 질소함유 헤테로 사이클릭 화합물의 제법
AR030571A1 (es) Proceso para preparar 2-(-piridin-4-ilamino)-pirido[2,3-d] pirimidinas e intermediarios en su sintesis
ES2096628T3 (es) Derivados heterociclicos.
ES2109936T3 (es) Derivados de piperacina.
AU4219897A (en) Process for the preparation of 3-amino-2-hydroxy-1-propyl ethers
EA200101050A1 (ru) Замещенные бензолактамные соединения
ES2273619T1 (es) Procedimiento de preparacion de derivados de feniltetrazol.
DK0681584T3 (da) Kondenserede, heterocykliske glutaminsyrederivater som antiproliferative midler
ES525712A0 (es) Un procedimiento para preparar nuevos derivados de la c-homo-9-oxaergolina
ES552486A0 (es) Un procedimiento para la obtencion de compuestos de 1-oxa-1-dertia cefalosporina.
PE20020610A1 (es) Compuestos hidroxietilamina tripeptidos mimeticos como inhibidores de la aspartil proteasa de vih
DE69011714D1 (de) Kalziumantagonisten.
DK248287D0 (da) Fremgangsmaade til fremstilling af chephalosporinderivater
PE20050578A1 (es) 6,7-DIHIDRO-5H-PIRAZOLO[1,2-a]PIRAZOL-1-ONA COMO INHIBIDORES DE LA LIBERACION EXTRACELULAR DE LAS CITOCINAS INFLAMATORIAS
YU48255B (sh) Racemski ili optički aktivni izohinolin derivati, postupak za njihovo dobivanje i postupak za dobivanje farmaceutskih preparata koji ih sadrže
ECSP993031A (es) Derivados de propenil cefalosporina

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed